Oral Presentation
Abstract Title:
Bulumtatug Fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study.
Nectin-4 ADC drug Bulumtatug Fuvedotin (BFv, 9MW2821) for the treatment of patients with recurrent or metastatic cervical cancer: Updated results from a Phase I/II study
Abstract Number: 28RO
Speaker:
Professor Huijuan Yang, Chief Physician, Doctoral Supervisor (Director of the Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center)
Presentation Time:
Local Time: June 17, 14:45-16:10
Beijing Time: June 17, 20:45-22:10
Poster Presentation
Abstract Title:
Preliminary results of Bulumtatug Fuvedotin (BFv, 9MW2821) in combined with Toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a Phase Ib/II Clinical Study.
Preliminary results of Bulumtatug Fuvedotin (BFv, 9MW2821) combined with Toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a Phase Ib/II clinical study
Abstract Number: 36P
Principal Investigators:
Professor Hanmei Lou, Chief Physician (Director of the Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital)
Professor Yudong Wang, Chief Physician (International Peace Maternity and Child Health Hospital, China Welfare Institute)
Presentation Time:
Local Time: June 18, 12:45-13:30
Beijing Time: June 18, 18:45-19:30
About Mabwell
Mabwell (688062.SH, 02493.HK) is an innovative biopharmaceutical company with a full industry chain layout. Always adhering to the vision of “Turning Innovation into Reality” and fulfilling the mission of “Exploring Life, Benefiting Health,” we provide patients with better efficacy and more accessible innovative biologics through original innovation to meet unmet clinical needs worldwide. Since its establishment in 2017, Mabwell has built an innovation system covering the entire drug R&D cycle, starting from antibody drug target discovery and molecular discovery, encompassing druggability research, preclinical research, clinical research, and production transformation, achieving a full industry chain layout integrating R&D, production, and marketing. We focus on oncology and age-related diseases, involving therapeutic areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and cardiovascular diseases. Leveraging internationally leading specialty technology platforms and R&D innovation capabilities, we have established a rich and competitive pipeline. Currently, we have 15 key products in preclinical, clinical, or marketing stages, including 11 innovative products and 4 biosimilars, of which 4 products are on the market, 1 product is under marketing review, and 2 products are in Phase III pivotal registration clinical trials. We have independently undertaken 1 national “Major New Drug Creation” major science and technology project, 2 national key R&D programs, and multiple provincial and municipal science and technology innovation projects. Mabwell is innovation-oriented and emphasizes industrial transformation. Our antibody and recombinant protein drug industrialization base, compliant with China NMPA, US FDA, and EU EMA GMP standards, has been put into operation in Taizhou, Jiangsu, and has passed the EU QP audit. Large-scale commercial production bases in Shanghai Jinshan and Taizhou, Jiangsu, are under construction. For more information, please visit: www.mabwell.com.
Forward-Looking Statements
The information contained in this press release may include certain forward-looking statements. These statements are inherently subject to significant risks and uncertainties. When using terms such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and other similar expressions, when related to the Company, the purpose is to indicate that they are forward-looking statements. The Company undertakes no obligation to continuously update these forward-looking statements.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, predictions, and understandings of the Company’s management regarding future events at the time the statements are made. These statements are not guarantees of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to future changes and developments in our business, competitive environment, political, economic, legal, and social conditions.
The Company, its directors, and employee agents assume no obligation (a) to correct or update any forward-looking statements contained on this website; and (b) any liability arising from the failure of any forward-looking statement to materialize or becoming inaccurate.